What a Pre-Mixed Reta+Cagri COA Should Include Identity confirmation (both compounds) Mass spectrometry showing two distinct peaks at the expected molecular weights: Retatrutide: ~4731 Da Cagrilintide: ~3775 Da HPLC chromatogram showing two well-resolved peaks at the expected retention times Purity testing (both compounds) HPLC purity for retatrutide: 97%+ (research-grade floor) HPLC purity for cagrilintide: 97%+ (research-grade floor) Each compound assessed independently not a single combined purity number Ratio quantification Reported as the actual mass ratio in the vial (e.g., "12.4 mg retatrutide : 2.6 mg cagrilintide" or "83% retatrutide / 17% cagrilintide by mass") Match to the labeled ratio (5:1 = 83.3% / 16.7%) Contamination testing Bacterial endotoxin Heavy metals Residual solvents Red Flags Specific to Pre-Mixed Blends COA reports a single purity number without breaking it down per compound
The effects of dual GLP-1/GIP receptor agonism on glucagon secretion: a review
When access to potentially life-changing treatment is determined by ability to pay rather than medical need, the divide between who gets healthier and who does not only grows wider.
Semaglutide, liraglutide, and dulaglutide have shown reductions in major adverse cardiovascular events (MACE) in patients with type 2 diabetes and established cardiovascular disease or multiple risk factors
This gap leaves open the possibility of unintended psychiatric effects, not because the drugs are inherently harmful, but because their impacts haven't been properly studied among users with mental health conditions
Our providers conduct comprehensive assessments to ensure safety and appropriateness before initiating any GLP1 therapy
